期刊
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
卷 1864, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.bbagen.2019.129437
关键词
Fabry disease; Lysosomal storage disease; Glycosphingolipids; Enzyme replacement therapy; Chaperone therapy; Rodent models
资金
- National Institutes of Health (NIH) [R01DK042667, K12HL141954, R21NS095627]
- National Research Service Award [F30DK113641]
- Career Development Program in Translational Glycosciences [K12HL141954]
- NIH [R24HL114474]
- [T32GM080202]
Background: Fabry disease is caused by alpha-galactosidase A deficiency. Substrates of this lysosomal enzyme accumulate, resulting in cellular dysfunction. Patients experience neuropathic pain, kidney failure, heart disease, and strokes. Scope of review: The clinical picture and molecular features of Fabry disease are described, along with updates on disease mechanisms, animal models, and therapies. Major conclusions: How the accumulation of alpha-galactosidase A substrates, mainly glycosphingolipids, leads to organ damage is incompletely understood. Enzyme replacement and chaperone therapies are clinically available to patients, while substrate reduction, mRNA-based, and gene therapies are on the horizon. Animal models exist to optimize these therapies and elucidate disease mechanisms for novel treatments. General significance: Recent newborn screening studies demonstrate that Fabry disease is the most common lysosomal storage disease. As many countries now include Fabry disease in their screening panels, the number of identified patients is expected to increase significantly. Better knowledge of disease pathogenesis is needed to improve treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据